STAPHYLOCIDAL MECHANISM OF PLATELET MICROBICIDAL PROTEIN

血小板杀菌蛋白的杀菌机制

基本信息

项目摘要

Traditionally, platelets have been thought to promote the development of endovascular infections such as infective endocarditis (lE), by providing a adhesive surface upon damaged endothelium for colonization by circulating microorganisms. In contrast, recent evidence suggests that platelets serve an important host defense role against the development of endovascular infections at sites of endothelial damage via local secretion of endogenous microbicidal peptides , termed thrombin-induced platelet microbicidal protein or tPMP. Preliminary studies revealed the following data: i) tPMP kills the most common endovascular pathogens in nM concentrations; ii) microbial strains from bacteremic patients without IE were significantly more susceptible in vitro to the microbicidal action of tPMP than strains from bacteremic patients with IE. This suggested that phenotypic tPMP- resistance provides the organism with a survival advantage as regards induction of IE; iii) tPMP is synergistic in combination with conventional antibiotics in the killing and growth.inhibition of S. aureus ; and iv) the bacterial cell membrane appears to be a primary target for tPMP-induced lethality.The overall purpose of the current proposal is to define the fundamental microbicidal mechanisms of tPMP against S. aureus, the most virulent and commonest overall cause of endovascular infections, by: i) quantifying tPMP binding to the staphylococcal membrane; ii) delineating the role of bacterial transmembrane potential in the staphylocidal actions tPMP; iii) identifying membrane assembly of tPMP and subsequent membrane permeabilization and pore formation by tPMP; and iv) defining the mechanisms of phenotypic tPMP resistance, using genetically-related staphylococcal strains from a common genomic background which differ phenotypically in tPMP susceptibility. These studies may eventually define novel staphylocidal targets or unique staphylocidal mechanisms. These studies will also provide a solid foundation for defining the staphylocidal domains of tPMP by molecular biologic techniques. tPMP will also serve as a design template for development of synthetic congeners with potent antimicrobial activity.
传统上,血小板被认为是促进 血管内感染,如感染性心内膜炎(IE), 粘附在受损内皮上的表面,用于通过循环 微生物的相反,最近的证据表明,血小板 一个重要的宿主防御作用,防止血管内的发展, 内皮损伤部位的感染,通过内源性 杀微生物肽,称为凝血酶诱导的血小板杀微生物肽 蛋白质或tPMP。初步研究揭示了以下数据:i)tPMP 以nM浓度杀死最常见的血管内病原体; ii) 无IE的菌血症患者的微生物菌株显著高于无IE的菌血症患者的微生物菌株。 在体外对tPMP的杀菌作用比菌株更敏感 来自患有IE的菌血症患者。这表明表型tPMP- 抗性为生物体提供了生存优势, 诱导IE; iii)tPMP与常规药物组合是协同的 抗生素对S.金黄色葡萄球菌;和iv) 细菌细胞膜似乎是tPMP诱导的主要靶点。 本提案的总体目的是界定 tPMP对S.金黄色,最 血管内感染的致命性和最常见的总体原因,通过:i) 定量tPMP与葡萄球菌膜的结合; ii)描绘 细菌跨膜电位在杀葡萄球菌作用中的作用 iii)鉴定tPMP的膜组装体和随后的 通过tPMP的膜透化和孔形成;和iv)定义 表型tPMP抗性的机制,使用遗传相关的 来自共同基因组背景的葡萄球菌菌株, tPMP易感性的表型。这些研究最终可能会定义 新的杀葡萄球菌靶标或独特的杀葡萄球菌机制。这些 研究还将为定义葡萄球菌杀 分子生物学技术研究tPMP的结构域。tPMP还将用于 作为设计模板,用于开发具有潜在毒性的合成同系物 抗菌活性

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

ARNOLD S BAYER其他文献

ARNOLD S BAYER的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('ARNOLD S BAYER', 18)}}的其他基金

Bicarbonate-Mediated Enhancement of Beta-Lactam-MRSA Killing: Mechanisms and Clinical Translatability
碳酸氢盐介导的 β-内酰胺-MRSA 杀灭增强:机制和临床可转化性
  • 批准号:
    10404600
  • 财政年份:
    2019
  • 资助金额:
    $ 19.29万
  • 项目类别:
Mechanisms and Circumvention of Daptomycin Resistance in Streptococcus mitis
轻链球菌达托霉素耐药机制及规避
  • 批准号:
    10064598
  • 财政年份:
    2017
  • 资助金额:
    $ 19.29万
  • 项目类别:
Mechanisms and Circumvention of Daptomycin Resistance in Streptococcus mitis
轻链球菌达托霉素耐药机制及规避
  • 批准号:
    10294249
  • 财政年份:
    2017
  • 资助金额:
    $ 19.29万
  • 项目类别:
Staphylococcal Adaptations to Platelet Microbicidal Protein
葡萄球菌对血小板杀菌蛋白的适应
  • 批准号:
    7371138
  • 财政年份:
    1996
  • 资助金额:
    $ 19.29万
  • 项目类别:
Mechanisms of Staphylococcal Co-Resistance to Daptomycin and Host Defense Peptide
葡萄球菌对达托霉素和宿主防御肽的共耐药机制
  • 批准号:
    8655509
  • 财政年份:
    1996
  • 资助金额:
    $ 19.29万
  • 项目类别:
Mechanisms of Staphylococcal Co-Resistance to Daptomycin and Host Defense Peptide
葡萄球菌对达托霉素和宿主防御肽的共耐药机制
  • 批准号:
    8843328
  • 财政年份:
    1996
  • 资助金额:
    $ 19.29万
  • 项目类别:
STAPHYLOCIDAL MECHANISM OF PLATELET MICROBICIDAL PROTEIN
血小板杀菌蛋白的杀菌机制
  • 批准号:
    2607842
  • 财政年份:
    1996
  • 资助金额:
    $ 19.29万
  • 项目类别:
Staphylocidal Mechanism of Platelet Microbicidal Protein
血小板杀菌蛋白的杀菌机制
  • 批准号:
    6433788
  • 财政年份:
    1996
  • 资助金额:
    $ 19.29万
  • 项目类别:
Staphylococcal Adaptations to Platelet Microbicidal Protein
葡萄球菌对血小板杀菌蛋白的适应
  • 批准号:
    7264240
  • 财政年份:
    1996
  • 资助金额:
    $ 19.29万
  • 项目类别:
Mechanisms of Staphylococcal Co-Resistance to Daptomycin and Host Defense Peptide
葡萄球菌对达托霉素和宿主防御肽的共耐药机制
  • 批准号:
    8370376
  • 财政年份:
    1996
  • 资助金额:
    $ 19.29万
  • 项目类别:

相似海外基金

Development of rapid detection method for drug-resistant bacteria in pulmonary MAC disease and search for new antibacterial agents
肺部MAC疾病耐药菌快速检测方法的建立及新型抗菌药物的寻找
  • 批准号:
    23K07930
  • 财政年份:
    2023
  • 资助金额:
    $ 19.29万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
Development of novel antibacterial agents using crystal structure-based drug screening
利用基于晶体结构的药物筛选开发新型抗菌剂
  • 批准号:
    23K07918
  • 财政年份:
    2023
  • 资助金额:
    $ 19.29万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
ATP Synthase as an emerging target for the pre-clinical development of broad-spectrum antibacterial agents against drug-resistant bacterial infections
ATP 合酶作为针对耐药细菌感染的广谱抗菌药物临床前开发的新兴靶标
  • 批准号:
    472342
  • 财政年份:
    2022
  • 资助金额:
    $ 19.29万
  • 项目类别:
    Operating Grants
Clinical application of a rapid assay for antibacterial susceptibility test of beta-lactams and carbapenems antibacterial agents using MALDI-TOF MS
MALDI-TOF MS快速测定β-内酰胺类和碳青霉烯类抗菌药物药敏试验的临床应用
  • 批准号:
    22K07406
  • 财政年份:
    2022
  • 资助金额:
    $ 19.29万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
Tailored and uniform fibre-like micelles as antibacterial agents.
定制且均匀的纤维状胶束作为抗菌剂。
  • 批准号:
    569719-2022
  • 财政年份:
    2022
  • 资助金额:
    $ 19.29万
  • 项目类别:
    Postgraduate Scholarships - Doctoral
Development of pH-responsive carriers for the controlled release of encapsulated acidifying and antibacterial agents
开发用于控制释放封装酸化剂和抗菌剂的 pH 响应载体
  • 批准号:
    531450-2018
  • 财政年份:
    2022
  • 资助金额:
    $ 19.29万
  • 项目类别:
    Collaborative Research and Development Grants
Novel silver nanoparticles as antibacterial agents
作为抗菌剂的新型银纳米颗粒
  • 批准号:
    521908-2018
  • 财政年份:
    2021
  • 资助金额:
    $ 19.29万
  • 项目类别:
    Collaborative Research and Development Grants
Development of pH-responsive carriers for the controlled release of encapsulated acidifying and antibacterial agents
开发用于控制释放封装酸化剂和抗菌剂的 pH 响应载体
  • 批准号:
    531450-2018
  • 财政年份:
    2021
  • 资助金额:
    $ 19.29万
  • 项目类别:
    Collaborative Research and Development Grants
Novel silver nanoparticles as antibacterial agents
作为抗菌剂的新型银纳米颗粒
  • 批准号:
    521908-2018
  • 财政年份:
    2020
  • 资助金额:
    $ 19.29万
  • 项目类别:
    Collaborative Research and Development Grants
Development of pH-responsive carriers for the controlled release of encapsulated acidifying and antibacterial agents.
开发用于控制释放封装酸化剂和抗菌剂的 pH 响应载体。
  • 批准号:
    531450-2018
  • 财政年份:
    2020
  • 资助金额:
    $ 19.29万
  • 项目类别:
    Collaborative Research and Development Grants
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了